TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03674437

Intervention type: BEHAVIORAL
Intervention: Traditional Neurocognitive Assessments
Description: Traditional Neurocognitive Assessments given with pen and paper

Intervention type: BEHAVIORAL
Intervention: Traditional Neurocognitive Assessments
Description: Traditional Neurocognitive Assessments given with pen and paper

Intervention type: BEHAVIORAL
Intervention: Traditional Neurocognitive Assessments
Description: Traditional Neurocognitive Assessments given with pen and paper

Intervention type: BEHAVIORAL
Intervention: Online Cognitive Battery (Cogsuite)
Description: Cognition (Cogsuite) for a battery that consists of seven measurements.

Intervention type: BEHAVIORAL
Intervention: Online Cognitive Battery (Cogsuite)
Description: Cognition (Cogsuite) for a battery that consists of seven measurements.

Intervention type: BEHAVIORAL
Intervention: Online Cognitive Battery (Cogsuite)
Description: Cognition (Cogsuite) for a battery that consists of seven measurements.
Study: NCT01475461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: double-dummy placebo tablets administered once-daily for 84-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 - 3mg
Description: PF-04937319 3mg administered as tablets once-daily for 84-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 - 20mg
Description: PF-04937319 20mg administered as tablets once-daily for 84-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 - 50mg
Description: PF-04937319 50mg administered as tablets once-daily for 84-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 - 100mg
Description: PF-04937319 100mg administered as tablets once-daily for 84-days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin - 100mg
Description: Sitagliptin 100mg administered as tablets once-daily for 84-days
Study: NCT04594837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTR Physical Therapy while wearing Robot group (Phase II)
Description: Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Only (Phase II)
Description: Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross over group for Physical Therapy n Sub-Acute group. (Phase II)
Description: Participants enrolled in the physical therapy only group will be given the option to re-enroll as a cross over participant to receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronic Stroke Subjects to receive robotic gait training therapy.
Description: Chronic stroke subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
Study: NCT00609947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor Zotarolimus-Eluting Coronary Stent
Study: NCT03539068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB-ED+ Treatment Arm
Description: Veterans who screen positive on one or more mental health screens in WEB-ED will be RCT-eligible. RCT-consenters randomly assigned to the WEB-ED+ Treatment are will receive::~* eHealth interfaces tailored to Veterans' VA and MHV enrollment needs (links for electronic VA enrollment, MHV and MHV premium status enrollment).~* Shared decision making (SDM) interfaces: Patient Decision aids (PTSD, depression, alcohol abuse); SDM educational video; videos).~* Access to study staff available through a toll-free number to assist both Veterans and providers, including addressing questions, problem-solving about or assisting with stuck points (e.g. getting screening results to the provider).
Study: NCT01721733

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743 15 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743 5 mg/kg
Study: NCT02511262

Intervention type: DEVICE
Intervention: illumigene® Mycoplasma Direct, illumipro-10
Description: DNA amplification assay
Study: NCT03052660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral administration preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral administration preoperatively
Study: NCT00458952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultratrace Iobenguane (MIBG) I 131
Description: Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
Study: NCT00003704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03498703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine Pill
Description: Azathioprine increase pregnancy rate in cases with recurrent implantaion failure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets
Study: NCT01053767

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Group B streptococcus (GBS) vaccine
Description: No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P2 study.
Study: NCT02657499

Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not

Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
Study: NCT03555253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience-Based Program for Support Partners of PwMS
Description: Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners. The MyHealios Resilience Program for PwMS and their Support Partners has been designed to be interactive and include skills-based activities led by the Resilience coach. This includes skills of communication, problem solving, and learning about resilience and cognition in MS.
Study: NCT03234920

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)
Description: 1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be 200 ml of fruit juice given twice daily
Study: NCT03250338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Description: Crenolanib will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: HAM regimen~FLAG-Ida

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: HAM regimen~FLAG-Ida

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: HAM regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitoxantrone
Description: HAM regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: FLAG-Ida regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fludarabine
Description: FLAG-Ida regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: FLAG-Ida regimen
Study: NCT01746589

Intervention type: DEVICE
Group type: OTHER
Intervention: bilateral myopic LASIK
Description: 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
Study: NCT01528319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MG-1
Description: Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.
Study: NCT04490577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates exercises are a combined exercise procedure including strengthening and stretching. Pilates exercises are performed with different equipment for example; therabands, mats, reformer, etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole-body vibration gives vibration to the body with a platform at different frequencies (Power-plate). The participant performed exercises on the platform.
Study: NCT03364777

Intervention type: OTHER
Intervention: emotional state
Description: anxiety or depression state evaluated by emotional scale
Study: NCT01112436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: periarticular injection of multidrug regimen
Description: periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: none of medication preoperatively and intraoperatively
Description: Patients in Group C wil receive none of medication preoperatively and intraoperatively
Study: NCT04944667

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TAVR planning
Description: TAVR planning without VR vs after VR
Study: NCT00485953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: risedronate 35 mg per week
Study: NCT05411172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastery Learning Model for Chemical, Biological, Radiological, and Nuclear threats and hazards (MLM-CBRN Education Program) on student nurses
Description: The MLM-CBRN Education Program was carried out with the students in the experimental group face-to-face as theoretical and practical education once a week for four weeks. . The data were collected before and right after the intervention and in the 1st and 3rd months after the intervention using the Personal Information Form, Nursing Student CBRN Knowledge Test, Nursing Student CBRN Attitude Scale, and Nursing Student CBRN Self-Efficacy Scale. Moreover, only the knowledge scores of the students in the experimental group were collected using the unit follow-up tests, which enabled us to check whether the Learning Objective related to the unit taught was achieved. During the skill training, the START Triage and JumpSTART Triage Skill Check List, Gas Mask Wearing-Removing Skill Check List, and Level C Clothes Wearing-Removing Skill Check List were scored for each student in the experimental group after observing the students twice.
Study: NCT02129868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop (Android Closed-Loop platform)
Description: The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.~The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop (Android Closed-Loop platform)
Description: The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.~The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes.
Study: NCT01216072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5 mg/day oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard MS DMTs
Study: NCT03359564

Intervention type: PROCEDURE
Intervention: micro endoscopic discectomy
Description: the patients receive micro endoscopic discectomy surgery therapy
Study: NCT00489801

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Exercise intervention and lifestyle counseling at centre or exercise intervention at home
Study: NCT00532168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir + emtricitabine + efavirenz
Description: tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir + emtricitabine + lopinavir-ritonavir
Description: tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir + emtricitabine + atazanavir-ritonavir
Description: tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
Study: NCT03656276

Intervention type: BEHAVIORAL
Intervention: Tool to improve Participation In Clinical Trials (ToPIC)
Description: The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
Study: NCT00756457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bracing
Description: Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bracing
Description: Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: Participants performed strengthening exercises progressively longer each time for up to 3 sets of 30 repetitions twice daily by the third visit. Exercises included bilateral heel raises, foot adduction/rear foot inversion with thera-tubing, and unilateral heel raises. Participants increased resistance by using thera-bands with higher levels of resistance over the 12 week period. The amount of resistance was progressed according to patient tolerance at each visit. Strengthening exercises were preceded by the control stretching exercises which constituted a warm up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
Study: NCT01627951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NF54
Description: Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF135
Description: Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF166
Description: Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
Study: NCT03809598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: See Mindfulness Based Cognitive Therapy (MBCT) Arm description
Study: NCT01612273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triflusal
Description: Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
Study: NCT04129047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnichroma (one shade universal) composite by Tokuyama
Description: Omnichroma is a single shade composite that is intended to have a color blending potential. It eliminates the shade matching procedures and makes it easier to avoid individual errors in shade matching in composite restorations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA
Description: a multiple shade universal composite that needs prior shade selection procedure
Study: NCT01240915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: once every 7 days for 1- 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem low dose
Description: 1-3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose at week 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem low dose
Description: Single dose at week 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem high dose
Description: Single dose Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose at week 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem high dose
Description: Single dose at week 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem high dose
Description: Single dose Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose at week 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem high dose
Description: Single dose at week 8
Study: NCT03423329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brufen
Description: Brufen Syrup

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brufen
Description: Brufen Syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cital
Description: Cital Cyrup

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cital
Description: Cital Cyrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Brufen
Description: Sansovit Syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Brufen
Description: Sansovit Syrup

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Brufen
Description: Sansovit Syrup
Study: NCT04060693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.5
Description: Investigational Medical Device collecting spectral raman data from tissue.
Study: NCT03836859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20μg/mL
Description: Study Eye (For subjects randomized to rhNGF group) Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).~Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).~Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle: formulation containing L-methionine as excipient.
Study: NCT00905905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe-Simvastatin
Description: Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
Study: NCT02474043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hep-Net Intervention
Description: The Hep-Net Intervention is a web-based questionnaire and tailored feedback system designed to increase readiness to change with respect to several behaviors. The behaviors include (1) reducing or quitting drug use; (2) using sterile equipment every time one injects drugs; (3) undergoing screening for hepatitis C; (4) receiving training to use naloxone to prevent death due to opioid overdose.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Clients receive health education and risk reduction counseling from a trained prevention specialist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Clients receive health education and risk reduction counseling from a trained prevention specialist.
Study: NCT03815864

Intervention type: DIAGNOSTIC_TEST
Intervention: Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
Description: Anti-AT1R antibodies were tested on pre-transplantation sera using ELISA kit (Lot #30, One Lambda, Canoga Park, CA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
Description: Anti-AT1R antibodies were tested on pre-transplantation sera using ELISA kit (Lot #30, One Lambda, Canoga Park, CA)